A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment
Levey AI, Qiu D, Zhao L, Hu WT, Duong DM, Higginbotham L, Dammer EB, Seyfried NT et al.. Brain : a journal of neurology, 2022-06-01
Topic: Risk, prevention and care in population studies
Dropout rates were 5.1% for atomoxetine and 2.7% for placebo, with no significant differences in adverse events. There were no significant treatment effects on cognition and clinical outcomes, as expected given the short trial duration. Atomoxetine was associated with a significant reduction in CSF Tau and pTau181 compared to placebo, but not associated with change in amyloid-β42. Atomoxetine treatment also significantly altered CSF abundances of protein panels linked to brain pathophysiologies, including synaptic, metabolism and glial immunity, as well as inflammation-related CDCP1, CD244, TWEAK and osteoprotegerin proteins. Treatment was also associated with significantly increased brain-derived neurotrophic factor and reduced triglycerides in plasma. Resting state functional MRI showed significantly increased inter-network connectivity due to atomoxetine between the insula and the hippocampus. Atomoxetine significantly reduced CSF Tau and pTau, normalized CSF protein biomarker panels linked to synaptic function, brain metabolism and glial immunity, and increased brain activity and metabolism in key temporal lobe circuits.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Levey, A. I., Qiu, D., Zhao, L., Hu, W. T., Duong, D. M., Higginbotham, L., et al. (2022). A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment. Brain : a journal of neurology. https://doi.org/10.1093/brain/awab452
Vancouver
Levey AI, Qiu D, Zhao L, Hu WT, Duong DM, Higginbotham L, et al. A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment. Brain : a journal of neurology. 2022. doi:10.1093/brain/awab452. PMID: 34919634.
BibTeX
@article{levey2022-34919634,
author = {Levey, A. I. and Qiu, D. and Zhao, L. and Hu, W. T. and Duong, D. M. and Higginbotham, L. and Dammer, E. B. and Seyfried, N. T. and others},
title = {{A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment}},
journal = {Brain : a journal of neurology},
year = {2022},
doi = {10.1093/brain/awab452},
pmid = {34919634},
url = {https://doi.org/10.1093/brain/awab452}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Dropout rates were 5.1% for atomoxetine and 2.7% for placebo, with no significant differences in adverse events.
- There were no significant treatment effects on cognition and clinical outcomes, as expected given the short trial duration.
- Atomoxetine was associated with a significant reduction in CSF Tau and pTau181 compared to placebo, but not associated with change in amyloid-β42.
- Atomoxetine treatment also significantly altered CSF abundances of protein panels linked to brain pathophysiologies, including synaptic, metabolism and glial immunity, as well as inflammation-related CDCP1, CD244, TWEAK and osteoprotegerin proteins.
- Treatment was also associated with significantly increased brain-derived neurotrophic factor and reduced triglycerides in plasma.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Effect size5.1%; 2.7%
- Evidence strengthHigh
How this study scored 79/100
Published in a leading specialty journal, and it is a randomised controlled trial. Scored zero for sample size because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multi-centre collaboration, so those were left out: it earned 46 of the 58 points we could judge it on, which is 79 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Brain : a journal of neurology) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 11 / 12 | A randomised controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (pubmed indexes it as a clinical or observational study) |
| Randomised / blinded | 1 / 2 | Randomised (as stated in the record) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 34919634) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 46 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 46 of the 58 points we could judge it on is 79 out of 100. |
| Total | 79 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related studies in Genetics
Also tagged “phase”
4 studies in the library carry the topic tag “phase”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 4 tagged studies.